Literature DB >> 11427181

Novel mutations in the 7-dehydrocholesterol reductase gene of 13 patients with Smith--Lemli--Opitz syndrome.

P E Jira1, R J Wanders, J A Smeitink, J De Jong, R A Wevers, W Oostheim, J H Tuerlings, R C Hennekam, R C Sengers, H R Waterham.   

Abstract

Smith--Lemli--Opitz syndrome (SLOS) is caused by mutations in the DHCR7 gene leading to deficient activity of 7-dehydrocholesterol reductase (DHCR7; EC 1.3.1.21), the final enzyme of the cholesterol biosynthetic pathway, resulting in low cholesterol and high concentrations of its direct precursor 7-dehydrocholesterol in plasma and tissues. We here report mutations identified in the DHCR7 gene of 13 children diagnosed with SLOS by clinical and biochemical criteria. We found a high frequency of the previously described IVS8--1 G > C splice acceptor site mutation (two homozygotes, eight compound heterozygotes). In addition, 13 missense mutations and one splice acceptor mutation were detected in eleven patients with a mild to moderate SLOS-phenotype. The mutations include three novel missense mutations (W182L, C183Y, F255L) and one novel splice acceptor site mutation (IVS8--1 G > T). Two patients, homozygous for the IVS8--1 G > C mutation, presented with a severe clinical phenotype and died shortly after birth. Seven patients with a mild to moderate SLOS-phenotype disclosed compound heterozygosity of the IVS8--1 G > C mutation in combination with different novel and known missense mutations.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11427181     DOI: 10.1017/S0003480001008600

Source DB:  PubMed          Journal:  Ann Hum Genet        ISSN: 0003-4800            Impact factor:   1.670


  10 in total

1.  Comprehensive population screening in the Ashkenazi Jewish population for recurrent disease-causing variants.

Authors:  L Shi; B D Webb; A H Birch; L Elkhoury; J McCarthy; X Cai; K Oishi; L Mehta; G A Diaz; L Edelmann; R Kornreich
Journal:  Clin Genet       Date:  2016-08-22       Impact factor: 4.438

2.  Smith-Lemli-Opitz Mutations in Unexplained Stillbirths.

Authors:  Karen J Gibbins; Uma M Reddy; George R Saade; Robert L Goldenberg; Donald J Dudley; Corette B Parker; Vanessa Thorsten; Halit Pinar; Radek Bukowski; Carol J Hogue; Robert M Silver
Journal:  Am J Perinatol       Date:  2018-02-12       Impact factor: 1.862

3.  Biological activities of 7-dehydrocholesterol-derived oxysterols: implications for Smith-Lemli-Opitz syndrome.

Authors:  Zeljka Korade; Libin Xu; Richard Shelton; Ned A Porter
Journal:  J Lipid Res       Date:  2010-08-11       Impact factor: 5.922

Review 4.  Smith-Lemli-Opitz syndrome.

Authors:  Andrea E DeBarber; Yasemen Eroglu; Louise S Merkens; Anuradha S Pappu; Robert D Steiner
Journal:  Expert Rev Mol Med       Date:  2011-07-22       Impact factor: 5.600

5.  Discordant phenotype and sterol biochemistry in Smith-Lemli-Opitz syndrome.

Authors:  Grace Koo; Sandra K Conley; Christopher A Wassif; Forbes D Porter
Journal:  Am J Med Genet A       Date:  2010-08       Impact factor: 2.802

6.  Relation between biomarkers and clinical severity in patients with Smith-Lemli-Opitz syndrome.

Authors:  Anna V Oláh; Gabriella P Szabó; József Varga; Lídia Balogh; Györgyi Csábi; Violetta Csákváry; Wolfgang Erwa; István Balogh
Journal:  Eur J Pediatr       Date:  2013-01-15       Impact factor: 3.183

7.  Analysis of 589,306 genomes identifies individuals resilient to severe Mendelian childhood diseases.

Authors:  Rong Chen; Lisong Shi; Jörg Hakenberg; Brian Naughton; Pamela Sklar; Jianguo Zhang; Hanlin Zhou; Lifeng Tian; Om Prakash; Mathieu Lemire; Patrick Sleiman; Wei-Yi Cheng; Wanting Chen; Hardik Shah; Yulan Shen; Menachem Fromer; Larsson Omberg; Matthew A Deardorff; Elaine Zackai; Jason R Bobe; Elissa Levin; Thomas J Hudson; Leif Groop; Jun Wang; Hakon Hakonarson; Anne Wojcicki; George A Diaz; Lisa Edelmann; Eric E Schadt; Stephen H Friend
Journal:  Nat Biotechnol       Date:  2016-04-11       Impact factor: 54.908

8.  Maternal ABCA1 genotype is associated with severity of Smith-Lemli-Opitz syndrome and with viability of patients homozygous for null mutations.

Authors:  Barbara Lanthaler; Elisabeth Steichen-Gersdorf; Barbara Kollerits; Johannes Zschocke; Martina Witsch-Baumgartner
Journal:  Eur J Hum Genet       Date:  2012-08-29       Impact factor: 4.246

9.  Development, behavior, and biomarker characterization of Smith-Lemli-Opitz syndrome: an update.

Authors:  Audrey Thurm; Elaine Tierney; Cristan Farmer; Phebe Albert; Lisa Joseph; Susan Swedo; Simona Bianconi; Irena Bukelis; Courtney Wheeler; Geeta Sarphare; Diane Lanham; Christopher A Wassif; Forbes D Porter
Journal:  J Neurodev Disord       Date:  2016-04-05       Impact factor: 4.025

Review 10.  Investigation of 7-dehydrocholesterol reductase pathway to elucidate off-target prenatal effects of pharmaceuticals: a systematic review.

Authors:  M R Boland; N P Tatonetti
Journal:  Pharmacogenomics J       Date:  2016-07-12       Impact factor: 3.550

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.